Christos Emmanouilides

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

Infections in Liver Transplant Recipients

Leptospirosis Complicated by a Jarisch-Herxheimer Reaction and Adult Respiratory Distress Syndrome: Case Report

Analysis of the Incidence of Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Registration and Compassionate-Use Trials of Ibritumomab Tiuxetan Radioimmunotherapy (RIT).

Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin’s Lymphoma (NHL).

CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study Durable responses after ibritumomab tiuxetan radioimmunotherapy for

R a ndomized C ontrolled T rial o f Y ttrium-90 - Labeled Ibritumomab T iuxetan R adioimmunothera py V ersus Rituximab I mmunotherapy f or P atients W ith R elapsed o r Refractory L ow-Grade, F ollicular, o r T ransformed B -Cell Non-Hodgkin's L ymphoma

Durable Responses after Ibritumomab Tiuxetan Radioimmunotherapy for CD20 + B -Cell Lymphoma: Long Term Follow -up of a

Pharmacokinetics of Ganciclovir Following Oral Valganciclovir Versus Intravenous Ganciclovir in Allogeneic Hematopoietic Stem-Cell Transplant Patients with Stable Graft-Versus-Host Disease of the Gastrointestinal Tract.

Safety o f Y ttrium-90 I britumomab T iuxetan Radioimmunothera py f or R elapsed L ow-Grade, F ollicular, o r Transformed N on-Hodgkin's L ymphoma